Follow
Fernando Aranda Vega
Fernando Aranda Vega
IdiSNA
Verified email at unav.es
Title
Cited by
Cited by
Year
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
8292014
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014
5402014
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
4842016
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
J Pol, E Vacchelli, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008866, 2015
3002015
Trial watch: IDO inhibitors in cancer therapy
E Vacchelli, F Aranda, A Eggermont, C Sautes-Fridman, E Tartour, ...
Oncoimmunology 3 (10), e957994, 2014
2442014
Trial Watch: Chemotherapy with immunogenic cell death inducers
E Vacchelli, F Aranda, A Eggermont, J Galon, C Sautès-Fridman, I Cremer, ...
Oncoimmunology 3 (3), e27878, 2014
1792014
Trial Watch: Peptide vaccines in cancer therapy
F Aranda, E Vacchelli, A Eggermont, J Galon, C Sautes-Fridman, ...
Oncoimmunology 2 (12), e26621, 2013
1472013
Trial Watch—Oncolytic viruses and cancer therapy
J Pol, A Buqué, F Aranda, N Bloy, I Cremer, A Eggermont, P Erbs, ...
Oncoimmunology 5 (2), e1117740, 2016
1392016
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
F Aranda, E Vacchelli, A Eggermont, J Galon, WH Fridman, L Zitvogel, ...
Oncoimmunology 3 (2), e27297, 2014
1372014
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008814, 2015
1122015
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
E Vacchelli, F Aranda, A Eggermont, J Galon, C Sautes-Fridman, ...
Oncoimmunology 3 (1), e27048, 2014
1072014
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
E Vacchelli, F Aranda, A Eggermont, J Galon, C Sautes-Fridman, ...
Oncoimmunology 3 (1), e27048, 2014
1072014
Acyl-CoA-binding protein is a lipogenic factor that triggers food intake and obesity
JM Bravo-San Pedro, V Sica, I Martins, J Pol, F Loos, MC Maiuri, ...
Cell Metabolism 30 (4), 754-767. e9, 2019
882019
Trial Watch: Toll-like receptor agonists in oncological indications
F Aranda, E Vacchelli, F Obrist, A Eggermont, J Galon, C Sautès-Fridman, ...
Oncoimmunology 3 (6), e29179, 2014
832014
Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression
N Díaz-Valdés, M Basagoiti, J Dotor, F Aranda, I Monreal, JI Riezu-Boj, ...
Cancer research 71 (3), 812-821, 2011
832011
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
A Buqué, N Bloy, M Perez-Lanzón, K Iribarren, J Humeau, JG Pol, ...
Nature Communications 11 (1), 3819, 2020
822020
Trial watch: dendritic cell-based anticancer therapy
N Bloy, J Pol, F Aranda, A Eggermont, I Cremer, WH Fridman, J Fučíková, ...
Oncoimmunology 3 (11), e963424, 2014
812014
Peptide inhibitors of transforming growth factor‐β enhance the efficacy of antitumor immunotherapy
D Llopiz, J Dotor, N Casares, J Bezunartea, N Díaz‐Valdés, M Ruiz, ...
International journal of cancer 125 (11), 2614-2623, 2009
802009
CD6 modulates thymocyte selection and peripheral T cell homeostasis
M Orta-Mascaró, M Consuegra-Fernández, E Carreras, R Roncagalli, ...
Journal of experimental medicine 213 (8), 1387-1397, 2016
792016
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer
F Aranda, N Bloy, J Pesquet, B Petit, K Chaba, A Sauvat, O Kepp, ...
Oncogene 34 (23), 3053-3062, 2015
792015
The system can't perform the operation now. Try again later.
Articles 1–20